Recently, April 2011, Both Vertex Telaprevir and Merck, Victrelis (boceprevir), hepatitis C drugs saw the same positive vote from FDA advisory committee voted to recommend drugs FDA approval. Telaprevir is more efficacious than boceprevir but may aggravate patients who have skin sensitivities, while boceprevir is more notorious for anemia. http://hepatitiscnewdrugs.blogspot.com/2011/05/vertex-ready-to-market-hepatitis-c-drug.html
At least one of the drugs is expected to be on the market in summer 2011.